ArticleBreast cancer research : BCR2026
Deubiquitination and stabilization of EIF4A3 by OTUB2 contributes to TPI1-mediated glycolysis and TNBC progression.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTumor cells rely on enhanced glycolytic capacity to facilitate cell growth and progression. However, the molecular mechanisms governing glycolysis in triple-negative breast cancer (TNBC) remain largely elusive. In this study, we elucidate the role of OTUB2 in regulating glycolysis in TNBC and delve into the mechanisms.
methodsWe utilized The Cancer Genome Atlas (TCGA) dataset to analyze the expressions of OTUB2, EIF4A3, and TPI1 in breast cancer tissues and specifically in triple-negative breast cancer (TNBC) tissues. qPCR and western blot experiments were performed to confirm the protein expressions of OTUB2, EIF4A3, and TPI1 in TNBC tissues and cell lines. Subsequently, overexpression and knockdown experiments followed by cell functional assays were conducted to elucidate the impact of OTUB2 on EIF4A3/TPI1-mediated TNBC malignant progression and related molecular mechanisms. Finally, a xenograft mouse model was established to verify the effect of OTUB2 in vivo.
resultsTCGA database indicated highly expressions of OTUB2, EIF4A3, and TPI1 in breast cancer tissues and TNBC tissues. Consistently, the mRNA and protein expressions of OTUB2, EIF4A3, and TPI1 were increased in TNBC tissues and cell lines, as compared to para-carcinoma tissues and MCF10A cells. OTUB2 knockdown inhibited cell proliferation, migration and invasion, and decreased glucose uptake, ATP level, lactate production, and ECAR, while the OTUB2 overexpression exhibited the opposite trends. Further data elucidated that OTUB2 stabilized the EIF4A3 protein via deubiquitination, and EIF4A3 interacted with TPI1 to stabilize its mRNA. Overexpression of EIF4A3 exacerbated TNBC malignant activities and glycolysis, while silencing TPI1 reversed these effects. In vivo, the knockdown of OTUB2 significantly inhibited tumor growth in a xenograft mouse model.
conclusionsWe conclude that OTUB2 deubiquitinates and stabilizes EIF4A3 to promote TNBC progression via TPI1-mediated glycolysis of tumor cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.